Potentially, patients who present with the ERG–TMPRSS2 fusion, but also show characteristics of the transition to path D (characterized by upregulation of MSR1, THY1, PILRA, BGN, and FAP), would be candidates for active surveillance, a tailored clinical management plan for the slow-growing, often indolent prostate cancer. This evidence concerns the gene FAP and prostate cancer.